Somatropin biosimilar - CristaliaAlternative Names: r-hGH Cristalia; Somatropin Cristalia
Latest Information Update: 06 Apr 2016
At a glance
- Originator Cristalia
- Class Growth hormones; Hormonal replacements
- Mechanism of Action Somatotropin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Somatotropin deficiency
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 07 Mar 2016 Phase-III clinical trials in Somatotropin deficiency (In children) in Brazil (SC)